Compare UDR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDR | ROIV |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | UDR | ROIV |
|---|---|---|
| Price | $35.50 | $22.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $40.12 | $21.94 |
| AVG Volume (30 Days) | 2.5M | ★ 6.7M |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | ★ 17.52 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,742,477,000.00 | $20,329,000.00 |
| Revenue This Year | $1.28 | N/A |
| Revenue Next Year | $3.02 | $376.94 |
| P/E Ratio | $81.02 | ★ N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $32.94 | $8.73 |
| 52 Week High | $46.47 | $22.45 |
| Indicator | UDR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 65.53 |
| Support Level | $34.66 | $20.14 |
| Resistance Level | $35.92 | $22.56 |
| Average True Range (ATR) | 0.56 | 0.70 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 42.67 | 76.35 |
UDR Inc is a real estate investment trust that owns, operates, acquires, renovates, develops, redevelops, disposes of, and manages multifamily apartment communities in targeted markets located in the United States. The company has two reportable segments; Same-Store Communities segment represents those communities acquired, developed, and stabilized; and Non-Mature Communities/Other segment represents those communities that do not meet the criteria to be included in Same-Store Communities, including, but not limited to, recently acquired, developed and redeveloped communities, and the non-apartment components of mixed-use properties. It generates key revenue from Same-Store Communities.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.